Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INP2
- Development stage
- Preclinical
- Lead developer
- Jilin University
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
INP2 is a novel anti-prolyl hydroxylase 2 (PHD2) cytosolic intrabody designed to protect against acetaminophen-induced liver injury (AILI). Developed by researchers at Jilin University, INP2 is synthesized from a human anti-PHD2 single-chain fragment variable (scFv) screened from a phage display library. It specifically binds to PHD2 in the cytoplasm, disrupting the interaction between PHD2 and hypoxia-inducible factor-1α (HIF-1α). This disruption inhibits PHD2-mediated hydroxylation and subsequent degradation of HIF-1α, thereby enhancing HIF-1α protein stability. In preclinical models, INP2 upregulates the HIF-1α/GPX1 axis, restoring glutathione biosynthesis (via upregulation of SLC7A11 and GPX1), improving redox homeostasis, and attenuating ferroptosis and oxidative stress in hepatocytes.
- Other names
- anti-PHD2 cytosolic intrabodyanti-PHD-2 cytosolic intrabodyanti-PHD 2 cytosolic intrabodyanti-PHD2 intrabodyanti-PHD-2 intrabodyanti-PHD 2 intrabody
02
Targets
EGLN1 (Prolyl hydroxylase domain-containing protein 2)
Beyond the preview
Go deeper on INP2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INP2.